What were the GSK (NYSE:GSK) CALM-1 results?

GSK (NYSE:GSK) said CALM-1 met its primary endpoint, with 50mg twice daily significantly reducing 24-hour cough frequency at week 12.

What were the GSK (NYSE:GSK) CALM-2 results?

GSK (NYSE:GSK) said CALM-2’s 50mg dose did not achieve statistical significance at week 24, while the 25mg dose also failed.

GSK (NYSE:GSK) reported that treatment-related adverse-event rates and severity were similar between camlipixant and placebo patients.

GSK (NYSE:GSK) will stop studying camlipixant for refractory chronic cough but continue the phase IIb BALANCE trial in IBS-D and IBS-M.

Image for illustrative purposes only. Not a real photo.

Written by Liezl GambePublished Jul 17, 2026, 11:05 AM

GSK ended camlipixant development for refractory chronic cough after CALM-2 failed its main efficacy target.
GSK shares fell as much as 4.5% and were down 3.2% at 1,894 pence in morning trading.
The company will continue evaluating camlipixant in a phase IIb trial involving two forms of irritable bowel syndrome.

GSK (NYSE:GSK) ended camlipixant development for chronic cough after CALM-2 missed its primary endpoint at 50mg.

CALM-1 succeeded at week 12, but CALM-2 failed at week 24, while 25mg missed in both trials.

GSK said key secondary endpoints also failed, while treatment-related adverse events were similar to placebo across both studies.

The company will publish the CALM data and continue the phase IIb BALANCE trial in two irritable bowel syndrome populations.

Following the announcement, GSK's share price was down 3.2% at 1,894 pence in London trading.

GSK acquired BELLUS Health for $2 billion in 2023, primarily gaining camlipixant and its chronic-cough research programme.

The company is strengthening its late-stage pipeline as major patent expiries are expected to begin affecting products from 2028.